The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


What do MITRA-FR and COAPT teach us about the percutaneous treatment of secondary mitral regurgitation?

EuroIntervention 2019;14:1713-1715. DOI: 10.4244/EIJV14I17A295

1. Department of Cardiovascular Surgery, The Mount Sinai Hospital, New York, NY, USA; 2. Department of Adult Cardiac Surgery, CHU Lyon, Inserm 1407, Lyon, France; 3. University of Rennes, CHU Rennes, Inserm, LTSI – UMR 1099, Rennes, France

The first two randomised controlled trials on secondary MR (MITRA-FR and COAPT) have recently been published1,2. These two studies had an excellent quality of follow-up modality with few lost patients, confirming the poor prognosis of this disease. The safety of MitraClip implantation (equivalent in both studies if we use the same definition of complications) and its efficacy to decrease mitral regurgitation (MR) (around 95% procedural success defined as residual MR ≤2+) are confirmed but we have to understand why two studies with apparently similar designs led to such different clinical results.

Several reasons could explain why MITRA-FR is negative:

– ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Transcatheter mitral valve repair with MitraClip in a large real-world experience: lessons from Germany